| Product Code: ETC13167512 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Pharmacovigilance Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Pharmacovigilance Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Pharmacovigilance Market Revenues & Volume, 2021 & 2031F |
3.3 North America Pharmacovigilance Market - Industry Life Cycle |
3.4 North America Pharmacovigilance Market - Porter's Five Forces |
3.5 North America Pharmacovigilance Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Pharmacovigilance Market Revenues & Volume Share, By Clinical Trial Phase, 2021 & 2031F |
3.7 North America Pharmacovigilance Market Revenues & Volume Share, By Service Provider, 2021 & 2031F |
3.8 North America Pharmacovigilance Market Revenues & Volume Share, By Type of Reporting, 2021 & 2031F |
3.9 North America Pharmacovigilance Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 North America Pharmacovigilance Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Pharmacovigilance Market Trends |
6 North America Pharmacovigilance Market, 2021 - 2031 |
6.1 North America Pharmacovigilance Market, Revenues & Volume, By Clinical Trial Phase, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Pharmacovigilance Market, Revenues & Volume, By Preclinical, 2021 - 2031 |
6.1.3 North America Pharmacovigilance Market, Revenues & Volume, By Phase I, 2021 - 2031 |
6.1.4 North America Pharmacovigilance Market, Revenues & Volume, By Phase II, 2021 - 2031 |
6.1.5 North America Pharmacovigilance Market, Revenues & Volume, By Phase III, 2021 - 2031 |
6.1.6 North America Pharmacovigilance Market, Revenues & Volume, By Phase IV, 2021 - 2031 |
6.2 North America Pharmacovigilance Market, Revenues & Volume, By Service Provider, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Pharmacovigilance Market, Revenues & Volume, By In-house, 2021 - 2031 |
6.2.3 North America Pharmacovigilance Market, Revenues & Volume, By Contract Outsourcing, 2021 - 2031 |
6.3 North America Pharmacovigilance Market, Revenues & Volume, By Type of Reporting, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Pharmacovigilance Market, Revenues & Volume, By Spontaneous Reporting, 2021 - 2031 |
6.3.3 North America Pharmacovigilance Market, Revenues & Volume, By Intensified ADR Reporting, 2021 - 2031 |
6.3.4 North America Pharmacovigilance Market, Revenues & Volume, By Targeted Spontaneous Reporting, 2021 - 2031 |
6.3.5 North America Pharmacovigilance Market, Revenues & Volume, By Cohort Event Monitoring, 2021 - 2031 |
6.3.6 North America Pharmacovigilance Market, Revenues & Volume, By EHR Mining, 2021 - 2031 |
6.4 North America Pharmacovigilance Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.2 North America Pharmacovigilance Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 North America Pharmacovigilance Market, Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031 |
6.4.4 North America Pharmacovigilance Market, Revenues & Volume, By Other End Users, 2021 - 2031 |
7 North America Pharmacovigilance Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Pharmacovigilance Market, Revenues & Volume, By Clinical Trial Phase, 2021 - 2031 |
7.2.1 United States (US) Pharmacovigilance Market, Revenues & Volume, By Clinical Trial Phase, 2021 - 2031 |
7.2.2 Canada Pharmacovigilance Market, Revenues & Volume, By Clinical Trial Phase, 2021 - 2031 |
7.2.3 Rest of North America Pharmacovigilance Market, Revenues & Volume, By Clinical Trial Phase, 2021 - 2031 |
7.3 North America Pharmacovigilance Market Revenues & Volume Share, By Service Provider, 2021 & 2031F |
7.3.1 United States (US) Pharmacovigilance Market, Revenues & Volume, By Service Provider, 2021 - 2031 |
7.3.2 Canada Pharmacovigilance Market, Revenues & Volume, By Service Provider, 2021 - 2031 |
7.3.3 Rest of North America Pharmacovigilance Market, Revenues & Volume, By Service Provider, 2021 - 2031 |
7.4 North America Pharmacovigilance Market, Revenues & Volume, By Type of Reporting, 2021 - 2031 |
7.4.1 United States (US) Pharmacovigilance Market, Revenues & Volume, By Type of Reporting, 2021 - 2031 |
7.4.2 Canada Pharmacovigilance Market, Revenues & Volume, By Type of Reporting, 2021 - 2031 |
7.4.3 Rest of North America Pharmacovigilance Market, Revenues & Volume, By Type of Reporting, 2021 - 2031 |
7.5 North America Pharmacovigilance Market, Revenues & Volume, By End User, 2021 - 2031 |
7.5.1 United States (US) Pharmacovigilance Market, Revenues & Volume, By End User, 2021 - 2031 |
7.5.2 Canada Pharmacovigilance Market, Revenues & Volume, By End User, 2021 - 2031 |
7.5.3 Rest of North America Pharmacovigilance Market, Revenues & Volume, By End User, 2021 - 2031 |
8 North America Pharmacovigilance Market Key Performance Indicators |
9 North America Pharmacovigilance Market - Export/Import By Countries Assessment |
10 North America Pharmacovigilance Market - Opportunity Assessment |
10.1 North America Pharmacovigilance Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Pharmacovigilance Market Opportunity Assessment, By Clinical Trial Phase, 2021 & 2031F |
10.3 North America Pharmacovigilance Market Opportunity Assessment, By Service Provider, 2021 & 2031F |
10.4 North America Pharmacovigilance Market Opportunity Assessment, By Type of Reporting, 2021 & 2031F |
10.5 North America Pharmacovigilance Market Opportunity Assessment, By End User, 2021 & 2031F |
11 North America Pharmacovigilance Market - Competitive Landscape |
11.1 North America Pharmacovigilance Market Revenue Share, By Companies, 2022 |
11.2 North America Pharmacovigilance Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here